Navigation Links
Xencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Date:10/1/2013

MONROVIA, Calif., Oct. 1, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies targeting the FcγRIIb pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion.

XmAb5871 is an Fc engineered monoclonal antibody that inhibits B cells by dual targeting CD19 and FcγRIIb. Amgen Inc. and Xencor entered into a collaboration and option agreement for XmAb5871 in December 2010. Under that agreement, Amgen has the option to acquire an exclusive worldwide license to XmAb5871, exercisable at any time before completion of a data review period following our planned subsequent Phase 2b proof-of-concept clinical trial. Xencor leads all research, development, and manufacturing activities for XmAb5871 until that time and is eligible for milestone payments.

"XmAb5871 represents a novel therapeutic strategy for engaging the FcγRIIb pathway to suppress autoimmune responses without B-cell depletion," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "This Phase 2a rheumatoid arthritis data is intended to inform a larger Phase 2 study and may support the potential use of XmAb5871 in other autoimmune diseases, such as lupus."

The Phase 2a portion of the clinical trial will evaluate biweekly doses of XmAb5871 in approximately 30 rheumatoid arthritis patients with active disease on stable non-biologic DMARD therapy. Endpoints include clinical markers of disease response.

XmAb5871 was well tolerated in the Phase 1a dose escalation part of the trial that enrolled 48 healthy male subjects and inhibited multiple biomarkers of immune function.

About Xencor, Inc.

Xencor is developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology. Xencor's internally-discovered programs include XmAb5871, in Phase 2a for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
2. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
3. Blood Centers of America Experiences Record Growth
4. Verenium Enters Agreement To Be Acquired By BASF
5. CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
6. Independent Living Centers Play A Vital Role In Helping Students Transition Out Of High School
7. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
10. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
11. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided for the ... for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
Breaking Biology Technology:
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
Breaking Biology News(10 mins):